five healthy volunteers received , in a randomised crossover design study , a 155 mg oral tablet and an intravenous infusion of 155 mg racemic hydroxychloroquine ( 200 mg hydroxychloroquine sulphate ) to assess the bioavailability of the commercially available tablet ( plaquenil , winthrop laboratories , australia ) .
C0993159
oral tablet
C0039225
tablet